July was another fabulous month and could have been even better if all of my medical holdings weren’t hit by the government. I was beyond ecstatic to see PGY, my #1 holding continue to break out, although it has since retreated a bit from the highs. My portfolio is currently at an ATH, but with pretty much all my companies reporting earnings next week and some undercurrents in the macro, I know it could go anywhere from here.
I made very few moves this quarter so this will be a pretty brief review with just short company thoughts below. I could see myself selling out of many positions next week, as I was disappointed in a few companies last quarter but wanted to wait another quarter.
Beyond my own holdings, I will say that I’m regretting selling out of Reddit, especially since I really generally like the company. I did not think they would re-accelerate revenue, and was clearly wrong. They had a great quarter, I will look at them again as earnings come in next week.
Here are my results to date and current portfolio:
JAN: -1.54%
FEB: +2.77%
MAR: -14.77%
APR: +7.91%
MAY: +24.92
JUN: +11.48%
JUL: +17.66%
YTD: +32.62%
(I think the huge off-hours drop from Jan 31 to Feb 1 is not reflected in the above monthly changes)
PGY:
They pre-released earnings and showed a revenue acceleration, from 18% to 30%, but have been on the move even before that happened. They also re-financed some debt which should improve net income moving forward. All eyes on the guide in earnings for me, hoping for $340M in revenue and an increase in network volume.
ALAB:
They’ve gotten a big boost from AI-related results. They have hinted to a big second half this year, so I’m hopeful this could be a big report coming up.
HIMS:
The Novo fallout, Canada misstep and poor results, coupled with the positive clinical results from HIMS’ GLP-1, has me feeling ever more confident in HIMS long term.
UPST:
Price started moving for the first time in a while, they’ve been on a run of great earnings but it feels like the market is still nervous. Another beat/raise and hopefully confidence is restored.
NBIS:
Pretty surprised they were down MoM with all the good news related to AI spend and results. If they deliver on their lofty guide, we should see a big spike.
Medical Stocks:
Big negative reactions to the bill. We’ll see how much it actually affects earnings.
The Others:
Not much news for many of my holdings, so we’ll see how earnings go and go from there.
Thanks for reading, and best of luck in August!